IBIO

TentativeAI MemoPost-earnings T+1

iBio

As of 2026-09-04/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Post-print repricing of FY2026 clinical transition • 2026-12-03

Base target: $1 / p=55% prob

Biggest risk

The company remains effectively pre-revenue and early clinical: FY2026 revenue was approximately $0.1 million, net loss was $33.0 million, and R&D expense rose to $19.6 million. IBIO-610 and IBIO-800 are preclinical or IND-enabling, while future execution may require additional capital and could create dilution through the $100 million-at-the-market facility [#SEC-8K-2026-08-28].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

iBio exited FY2026 with a clinical-stage pipeline, near-completion of IBIO-600 single-ascending-dose testing, additional IND-enabling programs, and management-reported cash runway into fiscal 2028. Successful IBIO-600 escalation or credible early clinical signals could materially improve investor confidence [#SEC-8K-2026-08-28].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-04

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

IBIO-610 and IBIO-800 development progression
iBio exited FY2026 with a clinical-stage pipeline, near-completion of IBIO-600 single-ascending-dose testing, additional IND-enabling programs, and management-reported cash runway into fiscal 2028.
Successful IBIO-600 escalation or credible early clinical signals could materially improve investor confidence [#SEC-8K-2026-08-28].

BearKey bullets

Additional equity issuance, including the Jefferies facility for up to $100 million of common stock, creates dilution risk [#SEC-8K-2026-08-28].
FY2026 revenue was approximately $0.1 million against a $33.0 million net loss, with R&D expense increasing to approximately $19.6 million [#SEC-8K-2026-08-28].
IBIO-600 is still in Phase 1 and the FY2026 release reported safety and escalation status, not clinical efficacy results.

WatchKey bullets

Post-print repricing of FY2026 clinical transition

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $1 (p=55%)

Target spread vs base: +56% / -48%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=55%)Bear Target: $1 (p=25%)

Commentary

The FY2026 company release is operationally constructive on pipeline advancement and cash runway, but the evidence remains low-coverage and development-stage. The peer set is not sufficiently direct for a standard-conviction comparison. The packet does not provide analyst reaction, consensus comparisons, or an independent post-release price-reaction series; missing data is not positive evidence. Social, options, short-interest, and employee-sentiment fields are unavailable rather than measured.

As of 2026-09-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

IBIO-610 and IBIO-800 development progression

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=55% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-12-03
Post-print repricing of FY2026 clinical transition
The FY2026 release reported $88.0 million of cash and investments, completion of 31 of 32 planned IBIO-600 single-ascending-dose participants without safety findings precluding escalation, and preparation for multiple-ascending-dose escalation. The release also reported $0.1 million of revenue, a $33.0 million net loss, and higher R&D spending, so the post-print balance is constructive on development progress but weak on current earnings power [#SEC-8K-2026-08-28].
Prob 55.00% • Move 6.00% • Priced-in 75.00%
EVENT2026-12-03
IBIO-600 multiple-ascending-dose escalation
iBio stated that it was preparing to advance IBIO-600 into the multiple-ascending-dose portion of its Phase 1 trial after dosing 31 of 32 participants across four single-ascending-dose cohorts with no safety findings that precluded dose escalation [#SEC-8K-2026-08-28].
Prob 60.00% • Move 18.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

IBIO-610 and IBIO-800 development progression
2027-09-04
IBIO-610 advanced into IND-enabling studies, while IBIO-800 entered IND-enabling development after development-candidate selection. The programs remain early-stage and dependent on nonclinical, CMC, regulatory, and financing execution [#SEC-8K-2026-08-28].
Prob 50% • Move 12% • Priced-in 50%

Risks

Additional equity issuance, including the Jefferies facility for up to $100 million of common stock, creates dilution risk [#SEC-8K-2026-08-28].
FY2026 revenue was approximately $0.1 million against a $33.0 million net loss, with R&D expense increasing to approximately $19.6 million [#SEC-8K-2026-08-28].
IBIO-600 is still in Phase 1 and the FY2026 release reported safety and escalation status, not clinical efficacy results.
IBIO-610 and IBIO-800 remain early-stage programs; supporting nonhuman-primate data for IBIO-610 included a small, non-statistically powered study [#SEC-8K-2026-05-12].
The available peer set is loose and not suitable for direct operating or valuation comparison.
The packet contains no usable analyst revisions, consensus surprise comparison, options data, short-interest data, social coverage, or independent post-release price-reaction analysis.

Peers

Symbol	Summary
CRDF	Only a loose same-sector, similar-market-cap comparator is established. No direct operating, program, or indication match is validated; it is excluded as a valuation anchor and used only for broad development-stage risk context.
LONA	Only a loose same-sector, similar-market-cap comparator is established. No direct operating, program, or indication match is validated; it is unsuitable as an operating or valuation anchor.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-04

Loading AI feed…

Symbol

Summary

CRDF

Only a loose same-sector, similar-market-cap comparator is established. No direct operating, program, or indication match is validated; it is excluded as a valuation anchor and used only for broad development-stage risk context.

LONA

Only a loose same-sector, similar-market-cap comparator is established. No direct operating, program, or indication match is validated; it is unsuitable as an operating or valuation anchor.